Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
421-440 of 1,782 trials

Epithelial Ovarian Cancer: Sentinel Node Detection Study

We are testing two tracers to see if they improve the detection of sentinel lymph nodes in patients with early-stage epithelial ovarian cancer. This may help in better understanding the cancer's spread and improving surgical outcomes.

Ovarian Epithelial Cancer>2 yearsEfficacy phase (II)Standard MedicinesGynecology and ObstetricsOncology

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

HER2-Positive Biliary Tract Cancer: GemCis with Trastuzumab and Pembrolizumab

We are studying a combination of treatments for people with HER2-positive biliary tract cancer to see if it improves response rates and overall survival. This trial aims to assess both the effectiveness and safety of the treatment.

Cholangiocarcinoma and Gallbladder Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

End-Stage Renal Disease: Rivaroxaban Dosing Study

We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.

Chronic Hemodialysis≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Early Breast Cancer: Elacestrant and Ribociclib Study

We are testing a new treatment combination of elacestrant and ribociclib for patients with hormone-sensitive early breast cancer. The goal is to see if this combination works better than standard therapies before surgery.

Hormone Receptor Positive HER2 Negative Breast Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Immune Thrombocytopenia: New Combination Therapy

We are studying a new treatment combining four medications for patients with immune thrombocytopenia. The trial will evaluate its effectiveness, safety, and impact on quality of life.

Immune ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Baricitinib for Uveitis in Children with Juvenile Idiopathic Arthritis

We are studying whether the oral medication baricitinib is safe and effective for children aged 2 to under 18 with active uveitis linked to juvenile idiopathic arthritis. This research aims to improve treatment options for these young patients.

UveitisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Lupus Nephritis: Obinutuzumab for Adolescents

We are studying the effects of obinutuzumab in adolescents with active lupus nephritis to see if it is more effective than a placebo. The trial also includes younger children to evaluate safety and how the drug works in them.

Lupus Nephritis>2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteNephrologyPediatricsRheumatology

Epcoritamab for Relapsed Primary CNS Lymphoma

We are studying the effects of epcoritamab in patients with relapsed primary diffuse large B-cell lymphoma of the CNS who have been treated with lenalidomide and rituximab. The trial aims to evaluate its effectiveness, safety, and impact on quality of life.

Relapsed and Refractory Primary Diffuse Large B-Cell Lymphoma of the CNS>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyNeurologyOncology

Asthma Management: BIRDIE Trial

We are exploring if we can safely extend the dosing schedule of two asthma medications for patients with severe eosinophilic and T2-high asthma. This study looks at whether this approach maintains asthma control.

Severe AsthmaConfirmation phase (III)No PlaceboStandard MedicinesAllergologyPulmonology

HIV Treatment: Doravirine/Tenofovir/Lamivudine Study

We are studying a combination of medications for people living with HIV who have a history of specific mutations. The goal is to see if this treatment helps maintain viral control and improves health over time.

HIV Disease1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Acute Myeloid Leukemia: DASATINIB Treatment Study

We are evaluating the effectiveness of DASATINIB for patients with acute myeloid leukemia who did not respond to previous treatments. The study aims to see if this medication can help reduce tumors and identify factors that predict response.

Acute Myeloid Leukemia≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Klinefelter Syndrome: Testosterone Treatment in Puberty

We are studying how testosterone replacement therapy affects boys with Klinefelter syndrome during puberty. This includes looking at changes in body composition, growth, and overall development.

Klinefelter Syndrome>2 yearsMonitoring phase (IV)Standard MedicinesEndocrinologyUrology

Heart Surgery: Buckberg vs. Del Nido Cardioplegia

We are comparing two heart protection solutions used during surgery to see which one better safeguards the heart and leads to fewer complications. This study is for patients undergoing isolated myocardial revascularization surgery.

Cardiovascular DiseaseMonitoring phase (IV)No PlaceboStandard Medicines

Colchicine for Heart and Kidney Health in Chronic Kidney Disease

We are studying whether low-dose colchicine can help prevent heart problems and slow kidney disease in people with moderate chronic kidney disease. This trial will also look at the safety of the treatment and its effects on inflammation.

Chronic Kidney Disease>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCardiologyNephrology

Stem Cell Transplantation vs. Immunosuppressive Therapy for Systemic Sclerosis

We are studying whether upfront stem cell transplantation is more effective than immunosuppressive medication for early diffuse cutaneous systemic sclerosis. This trial will help us understand the best treatment approach for improving survival and quality of life.

Diffuse Cutaneous Systemic SclerosisMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Peptide Receptor Radionuclide Therapy: LA-SSA Study

We are investigating how a long-acting medication affects radiation doses in tumors and normal tissues during treatment for certain cancers. This may help improve the effectiveness and safety of future therapies.

Neuroendocrine Tumors (NETs)3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Personalized Treatment Based on FLT3 Mutation

We are studying a new treatment strategy for patients with FLT3-positive AML, using a biomarker to tailor therapy. The goal is to see if this approach improves survival compared to standard treatments.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Sinonasal Carcinoma: Pembrolizumab and Chemotherapy

We are studying the safety and effectiveness of combining pembrolizumab with chemotherapy for patients with locally advanced sinonasal carcinoma. This trial aims to explore new treatment options for better outcomes.

Locally Advanced Sinonasal Carcinoma1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncologyOtolaryngology

IgM Monoclonal Gammopathy: Zanubrutinib and Rituximab Study

We are investigating whether a new treatment combining Zanubrutinib with Rituximab can improve nerve function in patients with IgM monoclonal gammopathy and related nerve damage. The study will also look at safety and how well patients tolerate the treatment.

Anti-MAG Neuropathy>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology